| 1. |
- Fischer, Marco P., et al.
(författare)
-
Field-resolved detection of the temporal response of a single plasmonic antenna in the mid-infrared
- 2021
-
Ingår i: Optica. - : Optica Publishing Group. - 2334-2536. ; 8:6, s. 898-898
-
Tidskriftsartikel (refereegranskat)abstract
- Unveiling the spatial and temporal dynamics of a light pulse interacting with nanosized objects is of extreme importance to widen our understanding of how photons interact with matter at the nanoscale and trigger physical and photochemical phenomena. An ideal platform to study light-matter interactions with an unprecedented spatial resolution is represented by plasmonics, which enables an extreme confinement of optical energy into sub-wavelength volumes. The ability to resolve and control the dynamics of this energy confinement on the time scale of a single optical cycle is at the ultimate frontier towards a full control of nanoscale phenomena. Here, we resolve in the time domain the linear behavior of a single germanium plasmonic antenna in the mid-infrared by measuring the complex optical field response in amplitude and phase with sub-optical-cycle precision, with the promise to extend the observation of light-matter interactions in the time domain to single quantum objects. Accessing this fundamental information opens a plethora of opportunities in a variety of research areas based on plasmon-mediated photonic processes and their coherent control, such as plasmon-enhanced chemical reactions and energy harvesting.
|
|
| 2. |
- Borrazzo, Cristian, et al.
(författare)
-
PET and MRI-guided focused ultrasound surgery for Neurological Applications
- 2016
-
Ingår i: 2016 IEEE NUCLEAR SCIENCE SYMPOSIUM, MEDICAL IMAGING CONFERENCE AND ROOM-TEMPERATURE SEMICONDUCTOR DETECTOR WORKSHOP (NSS/MIC/RTSD). - : IEEE. - 9781509016426
-
Konferensbidrag (refereegranskat)abstract
- Magnetic Resonance (MR) guided Focused Ultrasound Surgery (MRgFUS) technology, combined with High Intensity Focused Ultrasound (HIFU) beams, has opened to new therapeutic protocols for various pathological conditions. The success of this therapy relies on the accuracy of the guidance for therapy provided by thermal mapping of sonication, which is obtained with MR imaging. In addition, in recent years, multimodality Positron Emission Tomography and Magnetic Resonance Imaging (PET/MRI) imaging has been developed. This technique is able to provide simultaneous functional and soft tissue morphological imaging and, for this reason, it is particularly engaging for brain imaging. The key concept behind this work is to assess the feasibility of a brain-dedicated PET-and MRI-guided FUS device providing real-time evaluation of the outcome of the HIFU therapy. At first, a method to improve imaging capabilities of small-ring PET scanners will be presented. It will be showed that thanks to this method it is possible to obtain high tomographic spatial resolution with an affordable, brain-dedicated, PET scanner based on monolithic scintillation crystals and able to work as an insert in a MRI system. Moreover, simulations of an anthropomorphic phantom will be made in order to evaluate the effect of different HIFU protocols and, in addition, to investigate the capability of thermal maps provided by MRI for assessing the effect of the HIFU treatment. Finally, from the comparison of the spatial resolutions provided by each imaging technique (PET, MRI and thermal MRI) and the HIFU therapy, it will be possible to assess the feasibility of the proposed multimodality device. The system suggested in this work should be composed of a MRI scanner with a PET insert and a customized MRI-compatible focused ultrasound applicator. It could be very useful for the diagnosis and therapy of brain tumors thanks to the possibility of a real-time evaluation of the effect of the HIFU treatment. The protocol for the therapy could be executed in three main steps: the diagnosis of the pathological condition by means of fused anatomical imaging from MRI and functional imaging from PET (with different radiotracers) that allow to identify the region where apply the therapy, the ablation of the tumor by means of HIFU beams and the simultaneous evaluation of the thermal response of the tissues by means MRI thermal maps and, finally, the assessment of the outcome of the therapy by means, again, of PET/MRI hybrid imaging. The results suggest that PET and MRI-guided focused ultrasound surgery (PET/MRgFUS) could be an innovative, feasible and engaging technique for tumor ablation in the brain.
|
|
| 3. |
- Cipollini, Monica, et al.
(författare)
-
Polymorphisms within base and nucleotide excision repair pathways and risk of differentiated thyroid carcinoma
- 2016
-
Ingår i: DNA Repair. - : Elsevier BV. - 1568-7864. ; 41, s. 27-31
-
Tidskriftsartikel (refereegranskat)abstract
- The thyrocytes are exposed to high levels of oxidative stress which could induce DNA damages. Base excision repair (BER) is one of the principal mechanisms of defense against oxidative DNA damage, however recent evidences suggest that also nucleotide excision repair (NER) could be involved. The aim of present work was to identify novel differentiated thyroid cancer (DTC) risk variants in BER and NER genes. For this purpose, the most strongly associated SNPs within NER and BER genes found in our previous GWAS on DTC were selected and replicated in an independent series of samples for a new case-control study. Although a positive signal was detected at the nominal level of 0.05 for rs7689099 (encoding for an aminoacid change proline to arginine at codon 117 within NEIL3), none of the considered SNPs (i.e. rs7990340 and rs690860 within RFC3, rs3744767 and rs1131636 within RPA1, rs16962916 and rs3136166 in ERCC4, and rs17739370 and rs7689099 in NEIL3) was associated with the risk of DTC when the correction of multiple testing was applied. In conclusion, a role of NER and BER pathways was evoked in the susceptibility to DTC. However, this seemed to be limited to few polymorphic genes and the overall effect size appeared weak.
|
|
| 4. |
- Haller, Stephanie, et al.
(författare)
-
Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of (161)Tb-folate and (177)Lu-folate.
- 2016
-
Ingår i: EJNMMI research. - : Springer Science and Business Media LLC. - 2191-219X. ; 6:1
-
Tidskriftsartikel (refereegranskat)abstract
- The radiolanthanide (161)Tb has, in recent years, attracted increasing interest due to its favorable characteristics for medical application. (161)Tb exhibits similar properties to the widely-used therapeutic radionuclide (177)Lu. In contrast to (177)Lu, (161)Tb yields a significant number of short-ranging Auger/conversion electrons (≤50keV) during its decay process. (161)Tb has been shown to be more effective for tumor therapy than (177)Lu if applied using the same activity. The purpose of this study was to investigate long-term damage to the kidneys after application of (161)Tb-folate and compare it to the renal effects caused by (177)Lu-folate.
|
|
| 5. |
- Heslop, James A., et al.
(författare)
-
Concise Review : Workshop Review: Understanding and Assessing the Risks of Stem Cell-Based Therapies
- 2015
-
Ingår i: Stem Cells Translational Medicine. - : Oxford University Press (OUP). - 2157-6564 .- 2157-6580. ; 4:4, s. 389-400
-
Forskningsöversikt (refereegranskat)abstract
- The field of stem cell therapeutics is moving ever closer to widespread application in the clinic. However, despite the undoubted potential held by these therapies, the balance between risk and benefit remains difficult to predict. As in any new field, a lack of previous application in man and gaps in the underlying science mean that regulators and investigators continue to look for a balance between minimizing potential risk and ensuring therapies are not needlessly kept from patients. Here, we attempt to identify the important safety issues, assessing the current advances in scientific knowledge and how they may translate to clinical therapeutic strategies in the identification and management of these risks. We also investigate the tools and techniques currently available to researchers during preclinical and clinical development of stem cell products, their utility and limitations, and how these tools may be strategically used in the development of these therapies. We conclude that ensuring safety through cutting-edge science and robust assays, coupled with regular and open discussions between regulators and academic/industrial investigators, is likely to prove the most fruitful route to ensuring the safest possible development of new products.
|
|
| 6. |
- Malara, Natalia, et al.
(författare)
-
Multicancer screening test based on the detection of circulating non haematological proliferating atypical cells
- 2024
-
Ingår i: Molecular Cancer. - : BMC. - 1476-4598. ; 23:1
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- Background the problem in early diagnosis of sporadic cancer is understanding the individual's risk to develop disease. In response to this need, global scientific research is focusing on developing predictive models based on non-invasive screening tests. A tentative solution to the problem may be a cancer screening blood-based test able to discover those cell requirements triggering subclinical and clinical onset latency, at the stage when the cell disorder, i.e. atypical epithelial hyperplasia, is still in a subclinical stage of proliferative dysregulation. Methods a well-established procedure to identify proliferating circulating tumor cells was deployed to measure the cell proliferation of circulating non-haematological cells which may suggest tumor pathology. Moreover, the data collected were processed by a supervised machine learning model to make the prediction. Results the developed test combining circulating non-haematological cell proliferation data and artificial intelligence shows 98.8% of accuracy, 100% sensitivity, and 95% specificity. Conclusion this proof of concept study demonstrates that integration of innovative non invasive methods and predictive-models can be decisive in assessing the health status of an individual, and achieve cutting-edge results in cancer prevention and management.
|
|
| 7. |
- Mancina, Rosellina Margherita, et al.
(författare)
-
PSD3 downregulation confers protection against fatty liver disease.
- 2022
-
Ingår i: Nature metabolism. - : Springer Science and Business Media LLC. - 2522-5812. ; 4:1, s. 60-75
-
Tidskriftsartikel (refereegranskat)abstract
- Fatty liver disease (FLD) is a growing health issue with burdening unmet clinical needs. FLD has a genetic component but, despite the common variants already identified, there is still a missing heritability component. Using a candidate gene approach, we identify a locus (rs71519934) at the Pleckstrin and Sec7 domain-containing 3 (PSD3) gene resulting in a leucine to threonine substitution at position 186 of the protein (L186T) that reduces susceptibility to the entire spectrum of FLD in individuals at risk. PSD3 downregulation by short interfering RNA reduces intracellular lipid content in primary human hepatocytes cultured in two and three dimensions, and in human and rodent hepatoma cells. Consistent with this, Psd3 downregulation by antisense oligonucleotides in vivo protects against FLD in mice fed a non-alcoholic steatohepatitis-inducing diet. Thus, translating these results to humans, PSD3 downregulation might be a future therapeutic option for treating FLD.
|
|
| 8. |
- Stefania, Grimaudo, et al.
(författare)
-
PCSK9 rs11591147 R46L Loss-of-Function Variant Protects Against Liver Damage in Individuals with NAFLD.
- 2021
-
Ingår i: Liver international : official journal of the International Association for the Study of the Liver. - : Wiley. - 1478-3231. ; 41:2, s. 321-332
-
Tidskriftsartikel (refereegranskat)abstract
- The proproteinconvertasesubtilisin/kexin type 9(PCSK9) plays a key role in cholesterol homeostasis, and its inhibition represents an effective therapy to lower LDL-C levels. In this study, we examined the impact of the PCSK9 rs11591147 loss-of-function (LOF) variant on liver damage in a multicenter collection of patients at risk of nonalcoholic steatohepatitis (NASH), in clinical samples and experimental models.We considered 1,874 consecutive individuals at risk of NASH as determined by histology. The SNP rs11591147, encoding for the p.R46L variant of PCSK9,was genotyped by TaqMan assays. We also evaluated 1)PCSK9 mRNA hepatic expression in human liver, and 2)the impact of a NASH-inducing diet in mice with hepatic overexpression of human PCSK9.Carriers of PCSK9 rs11591147 had lower circulating LDL-C levels and were protected against NAFLD (OR0.42; 95%C.I0.22-0.81; P=0.01), NASH (OR0.48;95%C.I.0.26-0.87;P=0.01)and more severe fibrosis (OR0.55; 95%C.I.0.32-0.94; P=0.03) independently of clinical, metabolic and genetic confounding factors. PCSK9 hepatic expression was directly correlated with liver steatosis(P=0.03). Finally, liver-specific overexpression of human PCSK9 in male mice drives NAFLD and fibrosis upon a dietary challenge.In individuals at risk of NASH, PCSK9 was induced with hepatic fat accumulation and PCSK9 rs11591147 LOF variant was protective against liver steatosis, NASH and fibrosis, suggesting PCSK9 inhibition may be a new therapeutic strategy to treat NASH.
|
|
